Gene therapy of Dent disease type 1 in newborn ClC-5 null mice for sustained transgene expression and gene therapy effects

• Published in: Gene therapy Vol. 31; no. 11-12; pp. 563 - 571
• Main Authors: Lyu, Pin, Yadav, Manish Kumar, Yoo, Kyung Whan, Jiang, Cuili, Li, Qingqi, Atala, Anthony, Lu, Baisong
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.11.2024; Nature Publishing Group
• Subjects: 13; 13/51; 14; 14/1; 14/63; 42; 42/44; 631/61/201/2110; 692/699/1585; Animals; Animals, Newborn; Biomedical and Life Sciences; Biomedicine; Cell Biology; Channel gating; Chloride Channels - genetics; Chloride Channels - metabolism; Dent Disease - genetics; Dent Disease - therapy; Gene Expression; Gene Therapy; Gene transfer; Genetic Diseases, X-Linked - genetics; Genetic Diseases, X-Linked - therapy; Genetic Therapy - methods; Genetic Vectors - administration & dosage; Genetic Vectors - genetics; Genotype & phenotype; Human Genetics; Hypercalciuria; Immune response; Kidney - metabolism; Kidneys; Mice; Mice, Knockout; Mutants; Nanotechnology; Nephrolithiasis; Phenotypes; Promoter Regions, Genetic; Promoters; Proteinuria; Transgenes
• ISSN: 0969-7128; 1476-5462; 1476-5462
• DOI: 10.1038/s41434-024-00490-w

Dent disease type 1 is caused by changes in the chloride voltage-gated channel 5 ( CLCN5 ) gene on chromosome X, resulting in the lack or dysfunction of chloride channel ClC-5. Individuals affected by Dent disease type 1 show proteinuria and hypercalciuria. Previously we found that lentiviral vector-mediated hCLCN5 cDNA supplementary therapy in ClC-5 null mice was effective only for three months following gene delivery, and the therapeutic effects disappeared four months after treatment, most likely due to immune responses to the ClC-5 proteins expressed in the treated cells. Here we tried two strategies to reduce possible immune responses: 1) confining the expression of ClC-5 expression to the tubular cells with tubule-specific Npt2a and Sglt2 promoters, and 2) performing gene therapy in newborn mutant mice whose immune system has not fully developed. We found that although Npt2a and Sglt2 promoters successfully drove ClC-5 expression in the kidneys of the mutant mice, the treatment did not ameliorate the phenotypes. However, gene delivery to the kidneys of newborn Clcn5 mutant mice enabled long-term transgene expression and phenotype improvement. Our data suggest that performing gene therapy on Dent disease affected subjects soon after birth could be a promising strategy to attenuate immune responses in Dent disease type 1 gene therapy.